基石药业(02616.HK)肿瘤药完成中国首例受试者给药
基石药业(02616.HK)公布,avapritinib在正在进行的全球III期临床试验VOYAGER中实现首例中国受试者给药。研究主要评估avapritinib作为三线或四线疗法,相较於作为目前标准疗法的瑞戈非尼对於晚期胃肠道间质瘤「GIST」患者的安全性和疗效。试验的主要研究终点是无进展生存期。
Avapritinib是一款在研的口服精准药物,可选择性地有效抑制KIT和PDGFRA突变激(酉每),由基石药业合作夥伴Blueprint Medicines开发,其已向FDA(美国食药监局)提交了新药上市申请,有望成为基石药业第二款在美国获批上市的产品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.